How does someone want to lose weight to be beautiful and end up feeling ugly?
No cruzamento entre o desejo de transformação corporal e as promessas da medicina moderna, a influenciadora Dayanne Bezerra descobriu que o corpo guarda suas próprias lógicas. Ao usar Ozempic sob supervisão médica para emagrecer, ela alcançou o peso desejado — mas perdeu, no processo, a musculatura que pretendia realçar. Sua história não é apenas pessoal: é um espelho das tensões coletivas em torno de medicamentos usados fora de sua finalidade original, da pressão estética sobre figuras públicas e dos limites do que chamamos de uso responsável.
- Bezerra chegou ao consultório com um plano estético definido e saiu sem poder realizá-lo: a atrofia muscular glútea causada pelo emagrecimento severo inviabilizou completamente os procedimentos planejados.
- O choro nas redes sociais expôs a crueldade da ironia — ela havia usado o medicamento para ficar mais bonita e sentia que o resultado havia sido o oposto.
- Mesmo tendo seguido o caminho que ela própria pregava — prescrição médica, acompanhamento, cautela — as consequências não foram evitadas, revelando uma lacuna entre supervisão médica e compreensão plena dos riscos.
- O Ozempic, criado para tratar diabetes tipo 2, não distingue gordura de músculo durante a perda de peso acelerada, e o caso de Bezerra torna visível um efeito colateral pouco discutido publicamente.
- A repercussão do caso alimenta um debate crescente sobre o uso off-label de medicamentos para emagrecimento e a responsabilidade — médica, midiática e individual — nesse processo.
Na tarde de uma segunda-feira, Dayanne Bezerra deixou o consultório médico sem o que havia ido buscar. O plano era claro: aplicar silicone nos glúteos, tratar a pele flácida com Renuvion e sair com o resultado que havia imaginado. O que ouviu, em vez disso, foi que a musculatura da região havia atrofiado de forma severa demais para qualquer intervenção cirúrgica.
Irmã da influenciadora Deolane e figura pública por direito próprio, Bezerra havia perdido muito peso com o uso de Ozempic — o medicamento para diabetes que se tornou febre entre quem busca emagrecer. Ela sempre foi aberta sobre essa escolha. Quando foi flagrada se automedicando num aeroporto de São Paulo, respondeu com calma: tinha prescrição de nutricionista, seguia orientação médica, fazia tudo com responsabilidade. Chegou a aconselhar seus seguidores a fazerem o mesmo.
Mas o corpo cobrou um preço que ela não havia previsto. O emagrecimento foi além do planejado — ela própria reconheceu ter ficado magra demais. E quando o médico avaliou sua condição, a explicação foi direta: a perda excessiva de massa havia consumido os próprios músculos que ela queria realçar. Não havia tecido suficiente para trabalhar.
Nos Stories do Instagram, Bezerra desabou. Com a voz embargada, descreveu a ironia que a afligia: havia querido emagrecer para se sentir mais bonita e sentia que havia alcançado o efeito contrário. Em um vídeo após o outro, repetia que queria seus glúteos de volta. A dor emocional parecia tão intensa quanto a física.
O Ozempic foi desenvolvido pela Novo Nordisk para tratar diabetes tipo 2, não para emagrecer. Mas seu efeito supressor de apetite o transformou num dos medicamentos mais procurados fora de sua indicação original. O problema é que a perda de peso acelerada não distingue gordura de músculo — e quando o organismo precisa de energia, pode consumir seus próprios tecidos. No caso de Bezerra, o custo foi pago exatamente onde ela menos esperava.
Ela havia feito o que acreditava ser o caminho correto. E ainda assim, algo havia saído errado. Sua história toca em tensões que vão além do caso individual: o apelo das soluções farmacológicas, a pressão estética sobre quem vive sob os holofotes e a distância que pode existir entre acompanhamento médico e compreensão real das consequências.
Dayanne Bezerra sat in a doctor's office on Monday afternoon with a plan that had seemed straightforward: inject silicone into her buttocks, smooth out the loose skin with a Renuvion treatment, and emerge looking exactly as she'd imagined. Instead, she left with news that derailed everything. The muscles in that region had atrophied so severely that surgery was no longer an option.
Bezerra, sister of the well-known influencer Deolane and a social media personality in her own right, had lost a significant amount of weight using Ozempic, the diabetes medication that has become widely sought after for its dramatic slimming effects. She had been transparent about this choice, even when caught self-administering the drug at a São Paulo airport in May of the previous year. At that moment, she'd defended herself calmly, explaining that a nutritionist had prescribed it to her and that she was following proper medical guidance. She'd even offered advice to her followers: seek medical supervision, do things the right way, don't take anything without precautions.
But the body doesn't always cooperate with plans. The weight came off—so much weight that she'd become, by her own assessment, too thin. The doctor who knew her history looked at her and asked what was happening. When she explained her vision for the cosmetic work, he delivered the difficult truth: the excessive leanness had caused the gluteal muscles themselves to waste away. There was no longer enough tissue to work with.
On Instagram Stories, Bezerra broke down. She recorded herself in tears, her voice shaking as she described the cruel irony of the situation. She had wanted to lose weight to become more beautiful, she said, and instead she felt she had become less so. In one video she wept openly. In another, she kept returning to the same refrain: she wanted her buttocks back. The emotional weight of the unintended consequence seemed to hit her as hard as the physical one.
Ozempic, manufactured by Novo Nordisk, was never designed as a weight-loss drug. It was created to treat type 2 diabetes. But its appetite-suppressing effects have made it one of the most sought-after medications among people who want to slim down, and it has spawned a secondary market of off-label prescriptions, celebrity endorsements, and social media tutorials. Bezerra had positioned herself as someone doing it responsibly—with a doctor's sign-off, with caution, with the kind of medical oversight that distinguishes careful use from reckless self-medication.
What she hadn't anticipated, or perhaps hadn't been fully warned about, was that rapid weight loss at this scale could hollow out the very muscles that give the body its shape. The drug works by suppressing appetite and slowing digestion, but it doesn't discriminate between fat and muscle. When the body loses weight quickly, it can consume its own tissue for energy. In Bezerra's case, the cost was paid in the gluteal region—the exact area she'd been planning to enhance.
Her story sits at the intersection of several contemporary tensions: the desire for physical transformation, the promise of pharmaceutical solutions, the gap between medical supervision and full understanding of consequences, and the particular pressure on public figures to maintain a certain appearance. She had done what she believed was the responsible thing. And it had still gone wrong.
Citações Notáveis
My doctor said my buttocks have atrophied. Can you believe something like this?— Dayanne Bezerra, in Instagram Stories
I wanted to lose weight to be beautiful, and I ended up ugly. I want my buttocks back.— Dayanne Bezerra, in tearful Instagram Stories posts
A Conversa do Hearth Outra perspectiva sobre a história
Why did she feel comfortable defending Ozempic use so publicly, even after that airport incident?
Because she had a prescription. A doctor had signed off on it. In her mind, that made it legitimate—different from someone buying it on the black market or self-dosing without guidance.
But the doctor who prescribed it didn't warn her about muscle loss?
Apparently not in a way that registered as a real risk. Ozempic is prescribed for diabetes all the time. The muscle atrophy issue is real, but it's not always front and center in conversations about off-label weight loss.
So she was following the rules and still got hurt.
Exactly. That's what makes her story complicated. She wasn't reckless. She was trying to be careful. And the system—the doctor, the drug, the information available to her—still failed to prevent the outcome.
Do you think she'll stop using it?
The source doesn't say. But she's grieving what happened. Whether that translates to stopping, or just accepting the trade-off, we don't know yet.
What's the larger story here?
It's about how a medication designed for one purpose gets repurposed for another, and how the people using it may not fully understand what they're trading away.